BLA 125338 · Auxilium Pharms
Xiaflex
Collagenase Clostridium Histolyticum · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Feb 2, 2010
Approved uses
6
Original approval plus efficacy supplements
Registered trials
69
20 Phase 3, 1 recruiting
FAERS reports
5,433
1,380 serious, 61 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CORPORAL RUPTURE (PENILE FRACTURE) or OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE’S DISEASE Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies. In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile “popping” sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients [see Warnings and Precautions (5.2)] . Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention [see Warnings and Precautions (5.2)] . Because of the...
What it is approved for
From the label in effect Sep 17, 2026.
XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX is a combination of bacterial collagenases indicated for the treatment of: Adult patients with Dupuytren’s contracture with a palpable cord ( 1 ) Adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy ( 1 )
Mechanism: Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord. The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie’s plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2015 Supplement 87 · Efficacy LabelLetter
- May 15, 2015 Supplement 85 · Efficacy LetterLabel
- May 15, 2015 Supplement 88 · Efficacy LabelLetter
- Oct 20, 2014 Supplement 84 · Efficacy OrphanLetterLabel
- Dec 6, 2013 Supplement 61 · Efficacy OrphanLabelLetter
- Feb 2, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewOther
1 products under this application
- XIAFLEX · COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9MG · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Collagenase Clostridium Histolyticum" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's ContracturesPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01674634 · 715 participants · Start Sep 2012 · Primary completion Jul 2013
Drug: XIAFLEX / XIAPEX · For: Dupuytren's Contracture
Sites: Phoenix, Arizona; Tucson, Arizona; Encinitas, California · 25 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03428750 · 423 participants · Start Feb 5, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Scottsdale, Arizona; Encinitas, California; Long Beach, California · 26 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of Cellulite in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03446781 · 422 participants · Start Feb 8, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Glendale, Arizona; North Little Rock, Arkansas; Beverly Hills, California · 25 sites in all
- Study of AA4500 in the Treatment of Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01221597 · 418 participants · Start Sep 2010 · Primary completion Apr 2012
Drug: AA4500; Placebo · For: Peyronie's Disease
Sites: Homewood, Alabama; Phoenix, Arizona; Burbank, California · 34 sites in all
- Study of AA4500 in the Treatment of Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01221623 · 418 participants · Start Oct 2010 · Primary completion Mar 2012
Drug: AA4500; Placebo · For: Peyronie's Disease
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 34 sites in all
- EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT02724644 · 375 participants · Start Feb 2016 · Primary completion Sep 2016
Drug: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; Placebo Comparator · For: Edematous Fibrosclerotic Panniculopathy; Cellulite
Sites: Beverly Hills, California; Murrieta, California; Oceanside, California · 16 sites in all
- A Study of AA4500 in Men With Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01243411 · 348 participants · Start Nov 2010 · Primary completion Aug 2012
Drug: AA4500 · For: Peyronie's Disease
Sites: Burbank, California; Middlebury, Connecticut; New Haven, Connecticut · 39 sites in all
- Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's DiseasePivotal-lookingStatus unknown
University of CalgaryAcademic, hospital or other
NCT03000114 · 334 participants (planned) · Start Jan 2016 · Primary completion Jan 2021
Drug: XIAFLEX · For: Dupuytren Contracture; Dupuytren's Disease of Finger
Sites: Calgary, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,359
- contusion671
- swelling576
- pain506
- penile swelling479
- fracture of penis465
- penile contusion449
- injection site pain322
- penile pain311
- inappropriate schedule of product administration214
- injection site swelling213
- condition aggravated208
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 33 |
| 2011 | 153 |
| 2012 | 51 |
| 2013 | 20 |
| 2014 | 43 |
| 2015 | 361 |
| 2016 | 422 |
| 2017 | 332 |
| 2018 | 418 |
| 2019 | 656 |
| 2020 | 742 |
| 2021 | 589 |
| 2022 | 530 |
| 2023 | 303 |
| 2024 | 324 |
| 2025 | 304 |
| 2026 | 152 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xiaflex (Collagenase Clostridium Hist.)
2024 spending
$69.8M
Beneficiaries
4,346
6,420 claims
Per beneficiary
$16,067
$6,564.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,987,013 |
| 2021 | $46,325,487 |
| 2022 | $63,949,527 |
| 2023 | $66,001,126 |
| 2024 | $69,829,348 |
Part B: Xiaflex (Collagenase Clostridium Hist.) · HCPCS J0775
2024 spending
$80.0M
Beneficiaries
6,999
12,522 claims
Per beneficiary
$11,431
2024 ASP limit $68.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $55,724,586 |
| 2021 | $68,178,746 |
| 2022 | $70,414,259 |
| 2023 | $75,176,039 |
| 2024 | $80,008,759 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Analysis of Cellulite Treatment Modalities: A Systematic Review.
Lim SK, Gultekin G, Suresan S, et al. · Aesthetic Plast Surg 2025 · Systematic Review, Comparative Study
- What do we know about managing Dupuytren's disease cost-effectively?
Dritsaki M, Rivero-Arias O, Gray A, et al. · BMC Musculoskelet Disord 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy of collagenase Clostridium histolyticum combination therapies for Peyronie's disease: a systematic review and meta-analysis.
Guo Y, Yang Y, Mao Q, et al. · Sex Med Rev 2024 · Systematic Review, Meta-Analysis
- Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.
Smeraglia F, Del Buono A, Maffulli N · Br Med Bull 2016 · Systematic Review
- Collagenase Clostridium Histolyticum-aaes Injections for Volumetric Change of Cellulite Dimples and Gluteal Contouring.
Hartman NN, Almukhtar RM, Wood ES, et al. · Dermatol Surg 2023 · Clinical Trial
- Intralesional Injection Therapy and Atypical Peyronie's Disease: A Systematic Review.
Choi EJ, Xu P, El-Khatib FM, et al. · Sex Med Rev 2021 · Systematic Review
Sponsor: Auxilium Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.